{Reference Type}: Clinical Trial Protocol
{Title}: Design and rationale of a clinical trial to increase cardiomyocyte division in infants with tetralogy of Fallot.
{Author}: El Khoudary SR;Fabio A;Yester JW;Steinhauser ML;Christopher AB;Gyngard F;Adams PS;Morell VO;Viegas M;Da Silva JP;Da Silva LF;Castro-Medina M;McCormick A;Reyes-Múgica M;Barlas M;Liu H;Thomas D;Ammanamanchi N;Sada R;Cuda M;Hartigan E;Groscost DK;Kühn B;
{Journal}: Int J Cardiol
{Volume}: 339
{Issue}: 0
{Year}: 09 2021 15
{Factor}: 4.039
{DOI}: 10.1016/j.ijcard.2021.07.020
{Abstract}: Patients with Tetralogy of Fallot with pulmonary stenosis (ToF/PS), the most common form of cyanotic congenital heart disease (CHD), develop adverse right ventricular (RV) remodeling, leading to late heart failure and arrhythmia. We recently demonstrated that overactive β-adrenergic receptor signaling inhibits cardiomyocyte division in ToF/PS infants, providing a conceptual basis for the hypothesis that treatment with the β-adrenergic receptor blocker, propranolol, early in life would increase cardiomyocyte division. No data are available in ToF/PS infants on the efficacy of propranolol as a possible novel therapeutic option to increase cardiomyocyte division and potentially reduce adverse RV remodeling.
Using a randomized, double-blind, placebo-controlled trial, we will evaluate the effect of propranolol administration on reactivating cardiomyocyte proliferation to prevent adverse RV remodeling in 40 infants with ToF/PS. Propranolol administration (1 mg/kg po QID) will begin at 1 month of age and last until surgical repair. The primary endpoint is cardiomyocyte division, quantified after 15N-thymidine administration with Multi-isotope Imaging Mass Spectrometry (MIMS) analysis of resected myocardial specimens. The secondary endpoints are changes in RV myocardial and cardiomyocyte hypertrophy.
This trial will be the first study in humans to assess whether cardiomyocyte proliferation can be pharmacologically increased. If successful, the results could introduce a paradigm shift in the management of patients with ToF/PS from a purely surgical approach, to synergistic medical and surgical management. It will provide the basis for future multi-center randomized controlled trials of propranolol administration in infants with ToF/PS and other types of CHD with RV hypertension.
The trial protocol was registered at clinicaltrials.gov (NCT04713657).